Amneal Pharmaceuticals (AMRX) Total Liabilities (2018 - 2026)

Amneal Pharmaceuticals has reported Total Liabilities for 9 years, with the latest figure at $3.7 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 5.88% year-over-year to $3.7 billion in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 5.88% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 3.84% from the prior year.
• Total Liabilities was $3.7 billion for Q2 2026 at Amneal Pharmaceuticals, up from $3.6 billion in the prior quarter.
• The five-year high for Total Liabilities was $3.9 billion in Q2 2022, with the low at $3.5 billion in Q4 2023.
• Average Total Liabilities over 5 years is $3.6 billion, with a median of $3.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities grew 6.49% in 2022, then decreased 8.23% in 2023.
• Over 5 years, Total Liabilities stood at $3.6 billion in 2022, then declined by 4.5% to $3.5 billion in 2023, then increased by 4.59% to $3.6 billion in 2024, then grew by 3.84% to $3.7 billion in 2025, then retreated by 0.17% to $3.7 billion in 2026.
• The last three Total Liabilities figures came in at $3.7 billion (Q2 2026), $3.6 billion (Q1 2026), and $3.7 billion (Q4 2025), per Business Quant data.